Research Areas of the Schmidt Group

The group develops covalent binding enzyme inhibitors for neurodegenerative diseases, oncology and radiation therapy, preferentially via allosteric modulation or transient binding pockets. We are currently focused on inhibitors for kinases (GSK3, FLT3, NEK1) and the 20 S proteasome. This includes: • Target validation and identification by labelled compounds. • Development of fluorescent probes • Lead optimization • Proof-of-concept studies • in vivo toxicology in zebrafish embryo (Danio rerio)